The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma.
 
Ingo K. Mellinghoff
No Relationships to Disclose
 
Marta Penas-Prado
Consulting or Advisory Role - AGIOS; Lilly
Research Funding - Abbvie (Inst); Agios (Inst); AROG (Inst); DelMar Pharmaceuticals (Inst); DNAtrix (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Novartis (Inst); Orbus Therapeutics (Inst)
 
Katherine B. Peters
Consulting or Advisory Role - Abbvie; Agios; Eisai; Novocure
Research Funding - Abbvie; Agios; BioMimetix; Eisai; Genentech; Merck
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Alexion Pharmaceuticals; Boston Biomedical; Bristol-Myers Squibb; Celgene; Celldex; cortice; CytRx Corporation; Human Longevity, Inc; Insys Therapeutics; Merck; Nektar; NewGen Therapeutics; Notable Labs; Novartis; Novocure; Novogen; Oxigene; Pfizer; ProNAi; Roche/Genentech; Sunovion; Tocagen; Upsher-Smith; VBL Therapeutics; wellcome trust
 
Howard A. Burris
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); FORMA Therapeutics (Inst); Janssen (Inst); MedImmune (Inst); Mersana (Inst); Novartis (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PTC Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); TG Therapeutics (Inst); Valent Technologies (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Novartis
 
Elizabeth A. Maher
Honoraria - Lilly
Consulting or Advisory Role - Agios
Travel, Accommodations, Expenses - Agios; Lilly
 
Filip Janku
Stock and Other Ownership Interests - Trovagene
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; Immunome; Novartis; Sequenom; Trovagene
Research Funding - Agios; Astellas Pharma; BioMed Valley Discoveries; Deciphera; Fujifilm; Novartis; Piqur; Plexxikon; Roche; Symphony Evolution
Other Relationship - Bio-Rad
 
Gregory Michael Cote
Consulting or Advisory Role - 2nd.MD; Advance Medical; InfiniteMD
Research Funding - Agios (Inst); Amgen (Inst); Boston Biomedical (Inst); Eisai (Inst); Epizyme (Inst); Macrogenics (Inst); Merck KGaA (Inst); Otsuka (Inst); PharmaMar (Inst); Plexxikon (Inst)
 
Macarena Ines De La Fuente
Consulting or Advisory Role - Agios; Inovio Pharmaceuticals
 
Jennifer Clarke
Research Funding - Agios (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Agios
 
Lori Steelman
Employment - Agios; Infinity Pharmaceuticals
Stock and Other Ownership Interests - Agios; Infinity Pharmaceuticals
 
Kha Le
Employment - Agios
Stock and Other Ownership Interests - Agios
Patents, Royalties, Other Intellectual Property - Millennium
 
Yanwei Zhang
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Alison Sonderfan
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Diana Hummel
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Steven Schoenfeld
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Katharine Yen
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Shuchi Sumant Pandya
Employment - Agios
Stock and Other Ownership Interests - Agios
 
Patrick Y. Wen
Honoraria - Abbvie; AstraZeneca; Aurora Biopharma; Cavion; Gamestop Inc; Genentech/Roche; GW Pharmaceuticals; Immunomic Therapeutics; Insys Therapeutics; Kadmon; Lilly; Monteris Medical; Novartis; Novogen; Vascular Biogenics; VBI Vaccines; Vivus; ZIOPHARM Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca; Aurora Biopharma; Cavion; Gamestop Inc; Genentech/Roche; GW Pharmaceuticals; Immunomic Therapeutics; Insys Therapeutics; Kadmon; Lilly; Monteris Medical; Novartis; Novogen; Vascular Biogenics; VBI Vaccines; Vivus; ZIOPHARM Oncology
Speakers' Bureau - Merck
Research Funding - Abbvie (Inst); Agios (Inst); Angiochem (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); ImmunoCellular Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Sanofi/Aventis (Inst); Vascular Biogenics (Inst)